October 08, 2024 news

Advancing Cancer Drug Discovery with a Data-Driven Approach

We are pleased to share this article published in LaBiotech, which provides insights into how our data-driven approach is setting new standards in cancer treatment for solid tumors.

September 30, 2024 news

Roundtable: An exchange on biotechnology in northern Germany

In the latest Platform Lifesciences Issue 2/2024 we participated in a Roundtable and discussed together with partners within the biotechnology cluster, what challenges and chances there are in the industry - generally, and specifically in the northern german region.

September 26, 2024 press

Study reveals a path for the discovery of new targets and development of novel cancer therapies

Our new study reveals significant changes in the molecular characteristics of tumor samples within as little as 10 minutes after surgical removal. The findings underline the importance of rapid snap freezing of tissue samples to reliably capture cancer biology and reveal novel drug targets. Publishing in Cell Death & Disease, the study analyzed the impact of cold ischemia time on more than 1,800 tumor and matched normal tissue samples across four cancer types.

September 18, 2024 news

IRBLleida and Indivumed extend their collaboration agreement for high-quality biospecimen collection supporting precision oncology research

We visited our partner at the Hospital Universitari Arnau de Vilanova de Lleida and the Institut de Recerca Biomèdica de Lleida (IRBLleida) in Catalonia, Spain. Not only did we extend our collaboration agreement by another five years, we also recognized the IRBLleida as a Center of Excellence for their outstanding performance of tissue collection.

August 22, 2024 news

Article in "transkript": 10 minutes make all the difference

We are happy to share the “transkript” article (German). In this article, our CEO Prof. Dr. Juhl discusses how the first 10 minutes can make a crucial difference in precision oncology. He emphasizes the importance of high-quality tumor samples, the role of multi-omics data, and our commitment to identifying novel targets to improve the success rates of cancer therapies.

June 20, 2024 news

Interview in "BioTechnologie Kursbuch No. 37"

We are happy to be featured in this year's “BioTechnologie Kursbuch”. The interview from Georg Kääb with our CEO Prof. Dr. Hartmut Juhl covers an overview on the latest insights on the oncology R&D industry, what part AI has within this and what we believe truly matters.

June 11, 2024 news

The untapped power of multivariate analysis for target identification in cancer drug discovery - a LaBiotech Article

Is multivariate analysis the solution to identify targets in cancer drug discovery? We are pleased to be featured in the article from LaBiotech, that will provide an overview on the novel target identification process in pre-clinical oncology research, focusing on the computational/mathematical perspective into target ID.

April 15, 2024 news

Indivumed Omics Hub and Clinical Network Collaborations Powering Precision Medicine Research Publications

Indivumed GmbH announced the fourth research publication enabled by the Indivumed Omics Hub. An interface for members of the Indivumed Global Clinical Network, the Omics Hub provides clinicians with direct access to curated multi-omics data derived from their patients. With access to both individual and cohort data, the Omics Hub enables quick and efficient precision oncology research.

December 07, 2023 news

BIO Deutschland Yearbook 2023/2024

We are pleased to again be featured in the BIO Deutschland Yearbook for 2023/2024 and proud to be a part of the rapidly growing European biotech industry, looking forward to continuing our success in 2024. Read our feature interview and profile here.

December 11, 2023 news

Indivumed Hosts Onco AI-Med Annual Board Meeting in Hamburg

Onco AI-Med is an international collaborative alliance founded by Indivumed to advance personalized medicine in cancer by bringing together the combined knowledge and experience of oncologists from leading cancer clinics and research institutions around the world. Indivumed Therapeutics welcomed members of the Oncology Alliance For Individualized Medicine to its global headquarters in Hamburg, Germany for the Onco AI-Med annual board meeting.

November 28, 2023 news

Standardizing tissue quality: Your key to accurate early discovery insights

In precision oncology, tissue quality plays a pivotal role in maintaining data integrity. We explore the impact of standardizing tissue collection and processing on data quality, and how this helps enhance patient outcomes as well as our understanding of cancer.

September 21, 2023 news

Precision therapeutics: optimizing early discovery

Precision medicine tailors therapeutics to individual patients’ diseases, and is seen as the future of clinical practice. With significant time and financial investments being made in developing therapeutics, the ultimate success of patient-data driven precision therapies hinges on three main factors: the quality of the tissue samples, the associated molecular data, and the analysis used in their development.

July 28, 2023 news

Where the medicine of the future is already being lived in the present

More than 20 years ago, Indivumed set out to create a solid database for the individualized cancer therapy of the future. Today, founder and CEO Prof. Dr. Hartmut Juhl considers himself to have made considerable progress along this path, not least thanks to his company's unique database. In an interview with Wirtschaftsforum, the passionate entrepreneur talked about the future prospects.

July 24, 2023 news

Applied Molecular-Based Quality Control of Biobanked Samples for Multi-Omics Approach

Read our at MDPI newly published paper on "Applied Molecular-Based Quality Control of Biobanked Samples for Multi-Omics Approach".

June 06, 2023 news

Optimizing early discovery within precision therapeutics

Precision medicine involves tailoring a therapeutic to a patients’ disease. Here, we delve into the critical role played by the quality of the samples, the data, and the analysis in the development of these targeted therapies. Read the full article.

December 23, 2022 news

Ending the year - Today. Tomorrow. Together.

A review on 2022 and Indivumed's 20 year long history, and outlook, and thank you

Connect with us at Bio-Europe in Stockholm this year and join the panel discussion "I have a Dream" - AI for drug discovery

Meet the Indivumed Team on site, join our panel participation and get in touch with us in Stockholm from November 4-6, 2024.

October 09, 2024 poster

Poster Beck et al. 2024 Survival analysis for active modules using learned representations

September 26, 2024 publication

Von der Heyde, S. et al. Tumor specimen cold ischemia time impacts molecular cancer drug target discovery

September 16, 2024 poster

Poster Nale et al. 2024 Pan-Cancer, Multi-Omic Analysis of 'Hot' and 'Cold' Tumors Reveals Immunotherapy Relevant Signatures

August 22, 2024 publication

Ambeskovic, A. et al. Exon Skipping-based Subtyping of Colorectal Cancers, Gastroenterology (8/2024)

August 16, 2024 publication

Giovannini, S. et al. A comprehensive molecular characterization of a claudin-low luminal B breast tumor, Biology Direct 19:66 (2024)

April 30, 2024 publication

Scimeca, M. et. al Molecular profiling of a bladder cancer with very high tumour mutational burden, Cell Death Discovery 10:202 (2024)

April 08, 2024 poster

Poster Bischof et al. 2024 Deciphering chromosomal instability in consensus molecular Subtypes (CMS) in CRC: Insights from an integrative multi-omics approach

March 21, 2024 publication

Scimeca, M. et al. Genetically driven predisposition leads to an unusually genomic unstable renal cell carcinoma, Discover Oncology 15:80 (2024)

January 16, 2024 publication

Mengting Zhu et. al Genomic and transcriptomic profiling of hepatocellular carcinoma reveals a rare molecular subtype Discover Oncology 15:10 (2024)

October 21, 2023 poster

Poster Bischof et al. 2023 Combining cancer patient spatial transcriptomics and bulk rna-seq data to drive insights into NSCLC

October 09, 2023 publication

Yuyi, H. et al. A BRCA2 germline mutation and high expression of immune checkpoints in a TNBC patient Cell Death Discovery 9, 370 (2023)

October 02, 2023 publication

Yang, X. et al A primary luminal/HER2 negative breast cancer patient with mismatch repair deficiency Cell Death Discovery 9, 365 (2023)

September 03, 2023 publication

Michalska-Falkowska et al. MDPI 2023 Applied Molecular-Based Quality Control of Biobanked Samples for Multi-Omics Approach

August 26, 2021 poster

Poster Marshall et al. 2021 Multi-omics characterization markers of left and right-sided colorectal cancer